Centeno Christopher, Markle Jason, Dodson Ehren, Stemper Ian, Hyzy Matthew, Williams Christopher, Freeman Michael
Centeno-Schultz Clinic, Broomfield, CO, 80021, USA.
Regenexx, LLC, Des Moines, IA, 50321, USA.
J Exp Orthop. 2017 Nov 25;4(1):38. doi: 10.1186/s40634-017-0113-5.
Epidural steroid injections (ESI) are the most common pain management procedure performed in the US, however evidence of efficacy is limited. In addition, there is early evidence that the high dose of corticosteroids used can have systemic side effects. We describe the results of a case series evaluating the use of platelet lysate (PL) epidural injections for the treatment of lumbar radicular pain as an alternative to corticosteroids.
Registry data was obtained for patients (N = 470) treated with PL epidural injections presenting with symptoms of lumbar radicular pain and MRI findings that were consistent with symptoms. Collected outcomes included numeric pain score (NPS), functional rating index (FRI), and a modified single assessment numeric evaluation (SANE) rating.
Patients treated with PL epidurals reported significantly lower (p < .0001) NPS and FRI change scores at all time points compared to baseline. Post-treatment FRI change score means exceeded the minimal clinically important difference beyond 1 month. Average modified SANE ratings showed 49.7% improvement at 24 months post-treatment. Twenty-nine (6.3%) patients reported mild adverse events related to treatment.
Patients treated with PL epidurals reported significant improvements in pain, exceeded the minimal clinically important difference (MCID) for FRI, and reported subjective improvement through 2-year follow-up. PL may be a promising substitute for corticosteroid.
硬膜外类固醇注射(ESI)是美国最常见的疼痛管理方法,然而其疗效证据有限。此外,有早期证据表明所使用的高剂量皮质类固醇可能会产生全身副作用。我们描述了一个病例系列的结果,该系列评估了使用血小板裂解物(PL)硬膜外注射作为皮质类固醇的替代方法来治疗腰椎神经根性疼痛。
获取了接受PL硬膜外注射治疗的患者(N = 470)的登记数据,这些患者表现出腰椎神经根性疼痛症状且MRI结果与症状相符。收集的结果包括数字疼痛评分(NPS)、功能评定指数(FRI)和改良的单项评估数字评价(SANE)评分。
与基线相比,接受PL硬膜外注射治疗的患者在所有时间点的NPS和FRI变化评分均显著更低(p <.0001)。治疗后FRI变化评分均值在1个月后超过了最小临床重要差异。平均改良SANE评分显示治疗后24个月改善了49.7%。29名(6.3%)患者报告了与治疗相关的轻度不良事件。
接受PL硬膜外注射治疗的患者报告疼痛有显著改善,超过了FRI的最小临床重要差异(MCID),并在2年随访中报告了主观改善。PL可能是皮质类固醇的一种有前景的替代品。